Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

Table 7 Elderly AML front-line treatment options and median OS times

Treatment	N	Age, years	Median age, years	CR/CRi, %	OS, mo	Phase	Ref
Untreated	3367	≥65	77	n.g.	2	Retrosp.	[39]
HU+/-ATRA	99^a	>60	74	1	~3	III	[43]
HD-LEN	33	>60	71	30	4	II	[45]
LD-AraC+/-ATRA	103^a	>60	74	18	<5	III	[43]
CFA	112	>60	71	46	9.4	II	[40]
CFA + LD-AraC	54	>60	71	63	11.4	II	[42]
CFA + LD-AraC/DAC	60	>60	70	58	12.7	II	[44]
CFA + LD-AraC/DAC	118	>60	68	60	11.1	II	[44]
Allo-SCT	46	≥65	67	n.g.	22	Retrosp.	[39]
Intensive CTX	1856	≥65	74	n.g.	6	Retrosp.	[39]
Intensive CTX (3 + 7)	416	>65	67	57	12	III	[41]
BSC ↔ allo-SCT	352	≥60	n.g.	n.g.	9.0	Retrosp.	[47]
BSC ↔ allo-SCT	5480	≥65	78	n.g.	3.0	Retrosp.	[39]
DAC (DACO-16)	238	>65	74	18	7.7	III	[48]
AZA (AZA-AML-001)	241	>65	75	28	10.4	III	[24]
AZA-AAR	193	>17	77	18	12.6	Retrosp.	[46]
AZA + LEN	42	>60	74	28	15.9	I/II	[38]

^aIncluded 14 patients with high-risk MDS
n.g. CR complete response, CRi CR with incomplete blood count recovery, OS overall survival, n.g. not given, HU hydroxyurea, ATRA all trans retinoic acid, HD high-dose, LEN lenalidomide, LD-AraC low-dose cytarabine, CFA clofarabine, DAC decitabine, allo-SCT allogeneic stem cell transplantation, CTX chemotherapy, BSC best supportive care, AZA azacitidine, AML acute myeloid leukaemia, AAR Austrian Azacitidine Registry, MDS myelodysplastic syndrome

ISSN: 1756-8722